



City of Gainesville

Nature Centers Commission

Board Details

(12-members; 3-year terms) City Residency NOT Required

The Nature Centers Commission (NCC) assists the City Commission through recommendations and advice given in respect to developing programs, ordinances, use regulations and resource management policies as required to protect the natural system and other values to the Nature Centers of the City of Gainesville. The NCC was created by Ordinance 2062 (07/21/75); amended by Ordinances 2592 (04/27/81) and 3088 (12/17/84).

Overview

Size 12 Seats

Term Length 3 Years

Term Limit 2 Terms

Additional

Advisory Board Website

<http://www.cityofgainesville.org/ParksRecreationCulturalAffairs/NaturalResourcesandPrograms/SupportOrganizationsL>

Agendas and Minutes are located

upon request

Ordinance

Code 1960, § 2-113; Ord. No. 3088, § 3, 12-17-84





City of Gainesville

Nature Centers Commission

Board Roster



Hannah Gutner

1st Term Nov 07, 2019 - Sep 30, 2020

Appointing Authority City Commission

Category Student Member



Kathryn G Crummer

1st Term Oct 18, 2018 - Nov 01, 2021

Appointing Authority City Commission

Position Vice Chair



Leslie E Straub

1st Term Nov 15, 2018 - Nov 01, 2021

Appointing Authority City Commission



Leanne Sheffer

1st Term Feb 18, 2021 - Nov 01, 2022

Jessica W Wilson

1st Term Feb 21, 2019 - Nov 01, 2022

Appointing Authority City Commission

Position Treasurer



Ms. Cindy J. Boulware

1st Term Nov 07, 2019 - Nov 01, 2022

Appointing Authority City Commission

Position Secretary



Jonathan Reiskind

4th Term Jun 20, 2019 - Nov 01, 2022

Appointing Authority City Commission

Position Chair



Marylin Prado

1st Term Jan 16, 2020 - Nov 01, 2022



Mr. Bruce A. Blackwell

1st Term Nov 07, 2019 - Nov 01, 2022

Appointing Authority City Commission



Ms Karen Garren

1st Term Nov 05, 2020 - Nov 01, 2023



Michael J Hill

1st Term Nov 05, 2020 - Nov 01, 2023



Madilena E Campbell

1st Term Jun 03, 2021 - Nov 01, 2023



Penny Weber

8th Term Nov 05, 2020 - Nov 01, 2023

Appointing Authority City Commission

Category Friends Of Morningside Liaison

Profile

View current Advisory Board and Committee openings [online](#).

Dr. Richard L. Bennett
Prefix First Name Middle Initial Last Name Suffix

bennetr@ufl.edu
Email Address

14075 NW 26th Ave
Street Address Suite or Apt

Gainesville FL 32606
City State Postal Code

In what city district do you live? To find your district visit:

<http://www.cityofgainesville.org/CityCommission/CityCommissionDistricts.aspx> *

I do not live in Gainesville

Home: (352) 333-8107 Mobile: (352) 231-6997
Primary Phone Alternate Phone

Primary Phone Type

Home

Alternate Phone Type

Cell

University of Florida Research Assistant Professor
Employer Job Title

Which Boards would you like to apply for?

Nature Centers Commission: Submitted

PLEASE NOTE: You may only apply for two (2) City Advisory Boards/Committees each application cycle. A person may only be appointed to two (2) City Advisory Boards/Committees.

Do you claim any exemption to public record disclosure pursuant to FLA. STAT. Section 119?

Yes No

Review the text of FLA. STAT. Section 119 [HERE](#).

If yes, it is required that you submit a detailed explanation of exemption. Upload additional documentation if necessary.

Consistent with Section 2-247 of the City Code, board and committee members can be removed from the board or committee for poor attendance.

Interests & Experiences

Why are you interested in serving on the Nature Centers Commission?

In my role as a Scoutmaster in Scouts, BSA I routinely take part in hiking and biking trips around the Gainesville and Alachua County areas. I feel extremely lucky to have so many parks and other natural spaces in our community and it is imperative that we take good care of them. Our environment is directly linked to our health and well being. Taking good care of the environment directly benefits our way of life. I want to ensure that these spaces are well maintained and we protect them for years to come.

none

Members of all City of Gainesville Advisory Boards and Committees must only serve two (2) consecutive terms, except for the City Plan Board, Development Review Board and Historic Preservation Board. Members of the State Housing Initiatives Partnership must only serve three (3) terms.

How many terms have you served on this board or committee previously?

Have you been removed from any advisory board for attendance, behavior or another reason?

Yes No

If you answered yes to the question above, please explain: (upload a file if needed)

[CV - Bennett_6-2021.docx](#)

Upload a Resume

Please upload a file

Demographics

Ethnicity

Caucasian/Non-Hispanic

Gender

Male

Are you a City of Gainesville Employee?

Yes No

Are you a City of Gainesville Intern?

Yes No

Are you currently on a City Advisory Board/Committee?

Yes No

If yes, which Advisory Board/Committee?



Richard L. Bennett, Ph.D.

Research Assistant Professor

University of Florida, Department of Medicine

Contact:

2033 Mowry Rd.

CGRC Rm. 264, Box 103633

Gainesville, FL 32606

(352) 273-8333 (office)

email: bennettr@ufl.edu

Home:

14075 NW 26th Ave.

Gainesville, FL 32610

(352) 231-6997 (cell)

richandmary@mac.com

Education

Cornell University, Weill Graduate School of Medical Sciences, New York, NY

Ph.D. Molecular Biology, 2001

Thesis: Overexpression and characterization of the *Ustilago maydis* REC2 protein

Mentor: William K. Holloman, Ph.D.

Kalamazoo College, Kalamazoo, MI

B.A. Biology, Chemistry, 1993

Senior Thesis: Characterization of the Woodchuck Hepatitis X gene

Laboratory Experience

2016 - Present

Research Assistant Professor

Laboratory of Jonathan D. Licht

Dept. of Medicine, Division of Hematology/Oncology, University of Florida

University of Florida Health Cancer Center

Dr. Licht's laboratory studies how epigenetic dysfunction may drive cancer. My work has focused on characterizing how histone mutations that are frequently found in cancer may disrupt nucleosome structure to encourage aberrant gene expression and the development of cancer phenotypes. In addition, I have developed an in vitro assay to screen inhibitors of histone methyltransferase NSD2, and most recently begun work to characterize the epigenetic drivers of GNAQ-mutant uveal (eye) melanoma using a synthetic lethal CRISPR-Cas9 screening strategy. My bench work supports many of our collaborations and other projects in the lab. In addition, I am the day-to-day supervisor and mentor for Post-docs, undergraduate and graduate students working for Dr. Licht, and I manage lab administration such as helping to hire personnel, preparing grant applications, and preparing IACUC/EH&S protocols.

2009 - 2016

Research Assistant Professor

Laboratory of W. Stratford May

Dept. of Medicine, Division of Hematology/Oncology, University of Florida

In 2009 I applied for and obtained NIH R01 funding and State of Florida Department of Health funding (as a Co-Investigator) for the PKR project within Dr. May's lab. Thus, I developed a research group focused on determining the role of the interferon-inducible, dsRNA-activated Kinase PKR in tumorigenesis. Using transgenic mouse models that I developed, we observed that increased PKR expression promoted a preleukemic, myelodysplastic syndrome (MDS)-like phenotype. In addition, we discovered that PKR has a novel and previously unrecognized function in the nucleus to inhibit DNA damage response signaling by antagonizing ATM

activation. Thus, PKR transgenic mice demonstrated a mutator phenotype characterized by radiation-induced and age-associated genomic instability. I also managed the day-to-day activities of students, technicians and post-doctoral associates working on the PKR project. Furthermore, during this time I taught a summer seminar on the Molecular Basis of Cancer, a lecture series to the Department of Medicine Hem/Onc fellows covering the molecular biology of hematopoietic malignancies, served as course director for the Hem/Onc fellow wet lab, and mentored undergraduate students doing independent research in the Department of Microbiology.

2001 - 2009

**Postdoctoral Associate - Laboratory of W. Stratford May
Dept. of Medicine, University of Florida**

My post-doctoral work in Dr. May's laboratory focused on how the RAX-PKR cellular stress response pathway regulated the cell cycle and apoptosis. Although PKR had been well studied in the context of host anti-viral defense, the mechanism by which diverse cellular stress stimuli activated PKR was poorly characterized. My work focused on how PKR's only known cellular activator, RAX (also called PACT), regulated PKR function. During this time, I discovered that RAX phosphorylation on serine 18 activated PKR to inhibit eIF2 α -dependent protein synthesis. In addition, I discovered that RAX stimulated SUMOylation of p53 promoted phosphorylation of p53 and cell cycle arrest. I developed mouse and fly knockout models of RAX that established the RAX gene was required for mouse embryogenesis and fly nervous system development. Furthermore, using the crystal structure of the PKR-eIF2 α complex, I identified novel small molecule inhibitors of PKR activity. Significantly, for the years 2006 - 2009, I functioned as the day-to-day supervisor for the RAX-PKR group within Dr. May's lab to plan experiments, train students, hire new personnel, supervise other post-doctoral associates working on this project, and manage collaborations with other faculty members.

1994 - 2001

**Ph.D. Candidate - Laboratory of William K. Holloman
Dept. of Microbiology, Weill Medical College of Cornell University**

My thesis project in Dr. Holloman's lab examined the molecular biology of DNA repair in the fungal corn pathogen *Ustilago maydis* and focused specifically on the biochemistry of two proteins, Rad51 and Rec2, which are essential for homologous recombination. I optimized a method to purify Rec2 protein from an *E. coli* overexpression system and examined the recombination activities of the Rec2 protein *in vitro*. My work established that Rec2 alone is capable of promoting the homologous recognition and strand invasion, activities central to the process of homologous recombination. While in Dr. Holloman's lab, I also had roles in projects examining the function of the *REC1* gene in the cell division cycle of *U. maydis* and projects investigating the exonuclease activity of the Rec1 protein.

Sept. - Dec. 1993

**Graduate Research Assistant - Laboratory of Kenneth Marians
Memorial Sloan-Kettering Cancer Center**

Dr. Marians' lab studied the mechanism of DNA replication in *E. coli*. I specifically focused on the construction of site-specific DnaG (primase) mutants and the investigation of primase interaction with other components of the replication system through *in vitro* replication assays.

June - Sept. 1993

**Graduate Research Assistant - Laboratory of Maria Jasin
Memorial Sloan-Kettering Cancer Center**

Dr. Jasin's lab studied homologous recombination and gene targeting in mammalian cells. While in her lab, I set up and performed recombination assays in mouse ES cells and other mammalian cell lines.

1992-1993

**Research Assistant - Laboratory of Walter Ogston and Joyce Bock
Dept. of Biology, Kalamazoo College**

Studies focused on determining the role "minor" woodchuck hepatitis virus (WHV) genes play in both the production of virus and the pathogenesis of virus. My specific role was to generate genomes of WHV which were deficient in the production of spliced mRNA and to determine the effects of this mutation on virus production.

June - Sept. 1990

**Research Assistant - Laboratory of Alex Ninfa
Dept. of Biochemistry, Wayne State University**

Dr. Ninfa's lab studied the signal transduction system of nitrogen regulation in *E. coli*. My work included purification of the protein phosphatase/kinase NR_{II} and subsequent purification of phosphorylated fragments in order to determine the protein's site of autophosphorylation.

Awards and Honors

2019	Podium presentation award, Gordon Research Conference on epigenetics and cancer
2016	Best Basic Science Research, Junior Faculty, Department of Medicine, University of Florida
2013	Best Research by Junior Faculty, UF Health Cancer Center Research Symposium
2010	Excellence in Research Award, Department of Medicine, University of Florida
2006	Best Basic Cancer Research, Joint Cancer Conference of Florida Universities
2006	Amgen Young Investigator, Joint Cancer Conference of Florida Universities
2006	Award of Research Excellence, Department of Medicine, University of Florida
2004	Amgen Young Investigator, Joint Cancer Conference of Florida Universities
2001-2004	T32 Post-doctoral fellowship award (competitive), Cancer Biology Program, University of Florida

Professional Activities and Affiliations

2021 – Present	Associate Editor, Annals of Genetics
2020 – Present	Associate Editor, International Journal on Oncology and Radiotherapy
2016 – Present	Member, University of Florida Cancer Center, Mechanisms of Oncology working group
2014 – Present	Member, American Society of Hematology (ASH)
2003 – Present	Member, The American Association for Cancer Research (AACR)
2009 – 2016	Member, University of Florida Cancer Center, Molecular Oncology group
1991 – Present	Member, American Association for the Advancement of Science (AAAS)
2016 – Present	Member, Florida Society of Clinical Oncology (FLASCO)
2014 – 2018	Member, University Library Committee, University of Florida
2012 – 2018	Member, Student Financial Aid Committee, University of Florida
2016 – 2018	George Harrell Club, UF College of Medicine
2014 – 2015	Supporting Editor, International Journal of Cancer and Clinical Research
2014	Roundtable leader, AACR Grants Writing Workshop
2012 – 2015	Course Director, Div. of Hematology and Oncology Fellow Wet Lab
2002, 2003	Ad hoc peer review committee, American Society of Hematology
1999	Instructor, Cornell Institute for Biology Teachers
1998, 1999	Mentor, Cornell Science Challenge
1996	Peer Reviewer, Civilian Research and Development Foundation
1993	Teaching Assistant, Kalamazoo College, Physiological Ecology
1992	Teaching Assistant, Kalamazoo College, Organic Chemistry

Community Activities and Affiliations

2018 – present	Scoutmaster Troop 125, Scouts BSA Troop 125, Gainesville FL
2019 – present	Assistant Scoutmaster, Scouts BSA Troop 21, Gainesville FL
2015 – 2018	Assistant Scoutmaster, Scouts BSA Troop 125, Gainesville FL
2011 – 2015	Den Leader, Cub Scout Pack 124, Gainesville FL
2007 – 2015	Council Member, Celebration United Methodist Church, Gainesville FL

Peer-reviewed publications

Complete List at NCBI: <https://www.ncbi.nlm.nih.gov/myncbi/richard.bennett.2/bibliography/public?>

1. Prado, G., Kaestner, C.K., Licht, J.D., **Bennett, R.L.**, “Targeting epigenetic mechanisms to overcome venetoclax resistance” *Biochim Biophys Acta Mol Cell Res.* 2021 May 1;1868(8):119047. doi: 10.1016/j.bbamcr.2021.119047.
2. Licht, J.D., **Bennett, R.L.**, “Leveraging epigenetics to enhance the efficacy of immunotherapy” *Clin Epigenetics.* 2021 May 17;13(1):115. doi: 10.1186/s13148-021-01100-x.
3. Venugopal K., Nowialis P., Yang Feng, Y., Shabashvili, D.E., Berntsen, C.M., Krajcik, K.I., Taragjini, C., Zaroogian, Z., Casellas Román, H.L., Posada, L.M., Gunaratne, C., Li, J., Dupéré-Richer, D., **Bennett, R.L.**, Pondugula, S., Riva, a., Cogle, C.R., Opavsky, R., Law, B.K., Kubicek, S., Staber, P.B., Licht, J.D., Bird, J.E., Guryanova, O.A., “DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks.” *bioRxiv*, 2021: p. 2021.05.28.445639. *not peer-reviewed*
4. **Bennett, R. L.**, and **Licht, J. D.**, “Epigenetics.” In: Offermanns S., Rosenthal W. (eds) *Encyclopedia of Molecular Pharmacology*. 2021. Springer, Cham. https://doi.org/10.1007/978-3-030-21573-6_10061-1
5. **Bennett, R.L.**, Bele, A., Will, C. M., Small, E., Oyer, J., Nabet, B., Huang, X., Ghosh, R., Grzybowski, A., Yu, T., Zhang, Q., Riva, A., Lele, T., Shatz, G., Kelleher, N., Ruthenburg, A., Liphardt, J., Licht, J.D., “A mutation in the core of histone H2B represents a new class of oncogenic drivers” *Cancer Discov.* 2019 Oct;9(10):1438-1451. doi: 10.1158/2159-8290.CD-19-0393. PubMed PMID: 31337617.
6. Recker K.L, Norton, S., Sobh A., Riva, A., Chang, K., Kuznetsov, J., Durante, M., Flores, F., **Bennett, R.L.**#, Vakoc, C., Smalley, K., Harbour, W., Licht, J.D., “Synthetic Lethal Screen to Identify Molecular Mechanisms that Drive Uveal Melanoma” *UF Journal of Undergraduate Research*, 2019 Dec;21(1) DOI: <https://doi.org/10.32473/ufjur.v21i1.108370> (# **Faculty Research Mentor, Co-senior author**)
7. Huang, X., LeDuc, R.D., Fornelli, L., Schunter, A.J., **Bennett, R.L.**, Kelleher, N.L., Licht, J.D., “Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding” *J Biol Chem.* 2019 Aug 16;294(33):12459-12471.
8. Swaroop, A., Oyer, J.A, Will C.M., Huang X., Yu, W., Troche, C., Bulic, M., Qiang, J.W., Crispino, J. D., MacKerell, A., **Bennett, R. L.**, Kelleher, N., Licht, J.D., “An Activating Mutation of the NSD2 Histone Methyltransferase Drives Oncogenic Reprogramming In Acute Lymphocytic Leukemia” *Oncogene*, 2019 Jan;38(5):671-686
9. **Bennett R. L.**, Licht J. D., “Targeting epigenetics in cancer” *Annu Rev Pharmacol Toxicol.* 2018 Jan 6;58:187-207.
10. **Bennett R. L.**, Swaroop A., Troche C., Licht J. D., “The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer”; *Cold Spring Harb Perspect Med.* 2017 Jun 1;7(6).
11. Mahajan N., Wu H. J., **Bennett R. L.**, Troche C, Licht J. D., Weber J. D., Maggi L. B. Jr, Tomasson M. H., “Sabotaging of the oxidative stress response by an oncogenic noncoding RNA”; *FASEB J.* 2017 Feb;31(2):482-490.
12. Cheng, X., Byrne, M., Brown, K. D., Konopleva, M. Y., Kornblau, S. M., **Bennett, R.L.**#, May, W. S.#, “PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice”; *Blood.* 2015 Sep 24;126(13):1585-94. (# **Co-senior author**)
13. Byrne, M.* , **Bennett, R. L.***, Cheng, X., May, W.S. “The PIG-A assay can measure genomic instability and predict increased bone marrow blasts in the NHD13 model of MDS”; *Neoplasia.* 2014 Aug;16(8):627-33. doi: 10.1016/j.neo.2014.07.004. PMID: 25220590 (***Co-first author**)
14. Cheng, X.* , **Bennett, R. L.***, Liu, X., Byrne, M. & May, W. S., Jr. “PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis”, *Blood Cancer Journal* (2013) 3, e144; doi:10.1038/bcj.2013.42. PMID:24013665 (* **Co-first author**)
15. Xiangfei Liu*, **Richard L. Bennett***, Xiaodong Cheng, Michael Byrne, Mary K. Reinhard, W. Stratford May; “PKR regulates proliferation, differentiation and survival of murine hematopoietic stem/progenitor cells”; *Blood*, 2013 Apr 25;121(17):3364-74. PMID:23403623 (* **Co-first author**)
16. **Richard L. Bennett**, Aubrey L Carruthers, Teng Hui, Krystal R. Kerney, Xiangfei Liu, W. Stratford May; “Increased expression of the dsRNA-activated protein kinase PKR in breast cancer promotes sensitivity to doxorubicin”; *PLoS One.* 2012;7:e46040. PMCID: PMC3454339

Richard L. Bennett - CV

17. **Richard L. Bennett**, Yu Pan, Jaime Christian, Teng Hui, W. Stratford May; “The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and activation, leading to G1 arrest”; *Cell Cycle*. 2012 Jan 15;11(2):407-17. PMID: PMC3293386
18. **Richard L. Bennett**, William L. Blalock, Eun-Jung Choi, Young J. Lee, Yangping Zhang, Lei Zhou, S. Paul Oh, W. Stratford May; “RAX is required for fly neuronal development and mouse embryogenesis”; *Mech. Dev.*, 2008 vol. 125, p. 777 – 785.
19. Xuefang Cao, **Richard L. Bennett**; W. Stratford May; “c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis”; *J. Biol. Chem.*, 2008 vol. 283, No. 21, p. 14490 – 6.
20. **Richard L. Bennett**, William L. Blalock, Dean M. Abtahi, Yu Pan, Sue A. Moyer, W. Stratford May; “RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection”; *Blood*, 2006 vol. 108, No. 3, p. 821 – 829.
21. **Richard L. Bennett**, William L. Blalock, W. Stratford May; “Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition”; *J. Biol. Chem.*, 2004 vol. 279, No. 41, p. 42687 – 42693.
22. **Richard L. Bennett**, William K. Holloman; “A RecA Homologue in *Ustilago maydis* that is distinct and evolutionarily distant from Rad51 actively promotes DNA pairing reactions in the absence of auxiliary factors”; *Biochemistry*, 2001 vol. 40, No. 9, p. 2942-2953
23. William K. Holloman, **Richard L. Bennett**, Allyson Cole-Strauss, David O. Ferguson, Kenan Onel, Mara H. Rendi, Michael L. Rice, Michael P. Thelen, and Eric B. Kmiec, “Pathways of DNA Repair in *Ustilago maydis*”; *DNA Damage and Repair, Vol. 1: DNA Repair in Prokaryotes and Lower Eukaryotes*, Humana Press Inc. Totowa, NJ, 1998, p. 539 – 556
24. Kenan Onel, **Richard L. Bennett**, Paul Unrau, Andrew Koff, William K. Holloman; “The *REC1* Gene of *Ustilago maydis* couples DNA repair to nuclear division”; *Genetics*, 1996 vol. 143, p. 165 - 174.
25. Kenan Onel, Michael P. Thelen, David O. Ferguson, **Richard L. Bennett**, William K. Holloman; “Mutation Avoidance and DNA repair Proficiency in *Ustilago maydis* Are Differentially Lost with Progressive Truncation of the *REC1* Gene Product”; *Molecular and Cellular Biology*, 1995 vol. 15, No. 10, p. 5329 -5338.
26. Alexander J. Ninfa, **Richard L. Bennett**; “Identification of the Site of Autophosphorylation of the Bacterial Protein Kinase/Phosphatase NR_{II}”; *Journal of Biological Chemistry*, 1991, vol. 266, No. 11, p. 6888-6893.

Abstracts and Presentations

1. **Richard L. Bennett**, Darby Monagle, Amin Sobh, Keiran S. M. Smalley, J. William Harbour, Jonathan D. Licht. **Identification of essential proliferation and trametinib resistance mechanisms in GNAQ mutant uveal melanoma**. AACR annual meeting, April 2021 – *Lecture, Cell Growth and Signaling Pathways Mini-symposium*
2. Nupur Nigam, Benjamin J. Bernard, Kyunghye Burkitt, Sohyoung Kim, Yvette Robbins, **Richard L. Bennett**, Jonathan D. Licht, Vassiliki Saloura. **Immunomodulatory functions of SMYD3 in HPV-negative head and neck squamous cell carcinoma**. AACR annual meeting, April 2021
3. Michael F. Emmons, **Richard Bennett**, Alberto Riva, Bin Fang, Edward Seto, John M Koomen, Jonathan D. Licht, Keiran S.M. Smalley. **HDAC8 activity regulates stress induced phenotype switching in melanoma**. AACR annual meeting, April 2021
4. Daphne Dupere-Richer, Sayantan Maji, Alberto Riva, PhD, Gabrielle Quickstad, Marta Kulis, Darby Monagle, José I. Martín-Subero, **Richard L. Bennett** and Jonathan D. Licht. **KDM6A Controls Genes Modulating Immune Surveillance in Multiple Myeloma**, 62nd American Society of Hematology annual meeting, Dec. 5-8th 2020,
5. Jianping Li, Crissandra Piper, Daphne Dupere-Richer, Heidi Casellas Roman, Alok Swaroop, Catalina Troche, Jon Oyer, Christine Will, Alberto Riva, **Richard L. Bennett** and Jonathan D. Licht. **NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice**, 62nd American Society of Hematology annual meeting, Dec. 5-8th 2020,
6. Amin Sobh, Charlotte Kaestner, Jianping Li, Alberto Riva, **Richard L. Bennett** and Jonathan D. Licht. **Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma**, 62nd American Society of Hematology annual meeting, Dec. 5-8th 2020,

Richard L. Bennett - CV

7. Jianping Li, Catalina Troche, Julia Zhang, Jonathan Shrimp, Jacob Roth, Duohui Jing, Alok Swaroop, Marta Kulis, Jon Oyer, Christine Will, Daphne Dupere-Richer, Alberto Riva, Crissandra Pearce, Amin Sobh, Sharon Norton, **Richard L. Bennett**, Min Shen, Mathew Hall, Richard Lock and Jonathan D. Licht. **A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via blocking Receptor Auto-induction and *BIM/Bmf* Expression in ALL**, *Blood* 2019, 134 (supplement 1): 3758 <https://doi.org/10.1182/blood-2019-126910>
8. Kartika Venugopal, Daniil Shabashvili, Jianping Li, Luisa Posada, **Richard L. Bennett**, Yang Feng, Daphne Dupere-Richer, Alberto Riva, Santhi Pondugula, Jonathan Bird, Jonathan Licht and Olga Guryanova. ***DNMT3A* with Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks**, *Blood* 2019, 134 (supplement 1): 535 <https://doi.org/10.1182/blood-2019-128213>
9. **Richard L. Bennett** - **A mutation in the core of histone H2B represents a new class of oncogenic driver**, CSBC & PS-ON 2019 Annual investigators meeting, Sept 18-20, University of Minnesota
10. **Richard L. Bennett**. - **Screening for new vulnerabilities**, 2019 – Invited seminar speaker - Annual FACCA retreat, Miami FL June 13-14, 2019
11. Alberto Riva, **Richard L. Bennett**, Kartika Venugopal, Olga Guryanova, Jason O Brant, Jon D Licht. **DASA: a computational pipeline for differential ATAC-Seq analysis**. ISMB 2019, Basel, Switzerland, July 22-25 2019.
12. **Richard L Bennett** - **A mutation in the core of histone H2B represents a new class of oncogenic driver**, 2019 Gordon Research Conference on Cancer genetics and epigenetics, Podium presentation **Award winner**
13. Jianping Li, Catalina Troche, Alok Swaroop, Marta Kulis, Jon Oyer, Christine Will, Daphne Dupere-Richer, Alberto Riva, Crissandra Pipe, Sharon Norton, **Richard L. Bennett**, and Jonathan D. Licht. **A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance of Acute Lymphoblastic Leukemia**, *Blood* 2018 132:653; doi: <https://doi.org/10.1182/blood-2018-99-116309>
14. **Richard L. Bennett**, Aditya Bele, Christine M. Will, Eliza C. Small, Jon A. Oyer, Benham Nabet, Alberto Riva, Adrian Grzybowski, Rajarshi P. Ghosh, Tao Yu, Qiao Zhang, Alexander J. Ruthenburg, Jan Liphardt, George C. Shatz, Tanmay Lele, Jonathan D. Licht. **A mutation in the core of histone H2B represents a new class of oncogenic driver** CSBC & PS-ON 2018 Annual Investigators meeting, Sept. 25-26, at the NIH
15. Daphne Dupere-Richer, Jianping Li, Sayantan Maji, Crissandra Pipe, Sharon Norton, Teresa Ezponda, **Richard L Bennett**, and Jonathan D. Licht. **Loss of KDM6A/UTX Accelerate the Development of Multiple Myeloma**, *Blood* 2018 132:1004; doi: <https://doi.org/10.1182/blood-2018-99-113835>
16. **Bennett, R.L.** Bele, A., Will, C. M., Small, E., Oyer, J., Nabet, B., Riva, A., Grzybowski, A., Ghosh, R., Yu, T., Zhang, Q., Ruthenburg, A., Liphardt, J., Shatz, G., Lele, T., Licht, J.D., **A mutation in the core of histone H2B represents a new class of oncogenic driver**, 2018 Miami Epigenetics and Cancer Symposium
17. Alberto Riva, **Richard L. Bennett**, Jonathan D. Licht. **Damon: an open source framework for reliable and reproducible analysis pipelines**, ISMB 2017, Prague, Czech Republic, July 21-25 2017.
18. **Richard L Bennett**, Aditya Bele, Jonathan D. Licht., **A Cancer-Associated Mutation Of Histone H2B Destabilizes Chromatin Structure, Alters Gene Expression and Stimulates Neoplastic Growth**, Poster presentation, Physical Sciences of Oncology Network meeting, July 2017
19. **Richard L Bennett**, Jonathan D. Licht. **A Cancer-Associated Mutation Of Histone H2B Destabilizes Chromatin Structure, Alters Gene Expression and Stimulates Neoplastic Growth**. Oral presentation, Leukemia and Lymphoma Society, SCOR retreat October 2016
20. **Richard L. Bennett**, Xiaodong Cheng, Michael T. Byrne, Amalin Asous, Mohini Patel, Zeel Patel, W. Stratford May. **Increased PKR expression inhibits differentiation of hematopoietic stem cells**. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 194.
21. **Richard L. Bennett**, Michael T. Byrne, Xiaodong Cheng, Mohini Patel, Zeel Patel, Amalin Asous, W. Stratford May. **PKR inhibits hematopoietic stem cell differentiation**. *Blood* (2015) 126 (23): 2443. American Society of Hematology annual meeting, December 2015. <https://doi.org/10.1182/blood.V126.23.2443.2443>
22. Michael T. Byrne, **Richard L. Bennett**, Xiaodong Cheng, Christopher Carter, W. Stratford May. **Increased PKR Expression Promotes MDS Evolution to Acute Leukemia in the NHD13 Mouse Model**. *Blood* (2014) 124 (21): 1900. American Society of Hematology annual meeting, December 2014. <https://doi.org/10.1182/blood.V124.21.1900.1900>

23. Xiaodong Cheng, Michael T. Byrne, Kevin Brown, Marina Konopleva, Steven Kornblau, **Richard L. Bennett**, W. Stratford May. **PKR Inhibits the DNA Damage Response and Correlates with Poor Clinical Outcomes in AML.** *Blood* (2014) 124 (21): 1017 <https://doi.org/10.1182/blood.V124.21.1017.1017>
24. Xiaodong Cheng, Michael Byrne, **Richard L. Bennett**, Stratford William May. **PKR promotes genetic instability and evolution of MDS to acute leukemia in mice by negatively regulating DDR and DNA repair in a novel mechanism.** [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-1. doi:10.1158/1538-7445.AM2014-LB-1
25. Michael T. Byrne, **Richard L. Bennett**, Xiaodong Cheng, W. Stratford May. **PKR cooperates with an MDS driver mutation to worsen cytopenias and promote acute leukemia.** [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 75. doi:10.1158/1538-7445.AM2014-75
26. **Richard L. Bennett**, David A. Ostrov, W. Stratford May. **Novel inhibitors of the interferon-inducible, dsRNA-activated kinase PKR for myelodysplastic syndrome.** [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5673. doi:10.1158/1538-7445.AM2013-5673
27. Xiaodong Cheng, **Richard L. Bennett**, Xiangfei Liu, Stratford May. **Loss of PKR promotes leukemia progression by activating Bcl-2 to inhibit apoptosis.** [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4606. doi:10.1158/1538-7445.AM2013-4606
28. **Richard L. Bennett**, Yu Pan, Teng Hui, W. Stratford May, Jr., **The RAX/PACT-PKR stress-signaling pathway promotes p53 sumoylation and stability to induce G1 arrest.** [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2042. doi:1538-7445.AM2012-2042
29. Xiangfei Liu, **Richard L. Bennett**, Xiaodong Cheng, Vincent M. Alford, Tammy O. Flagg, Stratford W. May, Jr., **Transgenic expression of PKR induces a myelodysplastic syndrome/pre-leukemia-like condition in mice.** [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1350. doi:1538-7445.AM2012-1350
30. Xiaodong Cheng, **Richard L. Bennett**, Xiangfei Liu, Stratford W. May, Jr., **PKR induces apoptosis via PP2A activation and Bcl-2 dephosphorylation in IL-3 dependent murine bone marrow stem/progenitor cells.** [abstract] Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2009. doi:1538-7445.AM2012-2009
31. **Richard L. Bennett**, Teng Hui, Krystal Kerney, W. Stratford May, Jr, **PKR is a doxorubicin sensitivity biomarker for breast cancer.** [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 203. doi:10.1158/1538-7445.AM2011-203
32. **Richard L. Bennett**, Yu Pan, Teng Hui, Krystal R. Kerney, W. Stratford May, Jr.. **The RAX-PKR signaling axis enhances p53-mediated cell cycle arrest by a SUMOylation-dependent mechanism.** [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1090.
33. **Bennett, R. L.**, Ostrov, D. A., May, W. S.; **Identification of small molecule inhibitors of the novel target PKR as potential therapy for breast cancer.** [abstract]. In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4673.
34. Pan, Y., **Bennett, R. L.**, May, W. S.; **RAX activates tumor suppressor p53**, *Blood* (2006) 108 (11): 1449. American Society of Hematology annual meeting. <https://doi.org/10.1182/blood.V108.11.1449.1449>
35. **Bennett, R. L.**, Blalock, W. L., Moyer, S. A., May, W. S.; **RAX-dependent PKR activation is required for host antiviral defense after vesicular stomatitis virus infection**, American Association for Cancer Research, 2006 annual meeting. Proc Amer Assoc Cancer Res, Volume 47, 2006. Abstract nr 4450
36. Abtahi, F. M., Blalock, W. L., **Bennett, R. L.**, May, W. S.; **RAX, the cellular activator of PKR, is required for stress induced apoptosis and the maintenance of normal cell growth in MEF cells**, American Association for Cancer Research, 2005 annual meeting In: Proc Amer Assoc Cancer Res, Volume 46, 2005. Abstract nr 823

Richard L. Bennett - CV

37. Blalock, W. L., **Bennett, R. L.**, Abtahi, F. A., May, W. S.; **INF-gamma/TNF-alpha Hypersensitivity in Fanconi Anemia Group C Null Fibroblasts Is Relieved by Expression of the PKR Activator, RAX/PACT**, International Society of Experimental Hematology; 2004 annual meeting
38. **Bennett, R. L.**, Blalock, W. L., May, W. S.; **Phosphorylation of RAX, the PKR activator, on serine 18 following IL-3 withdrawal is required for PKR activation and inhibition of protein synthesis**, American Association for Cancer Research, 2004 annual meeting
39. **Bennett, R. L.**, Blalock, W. L., May, W. S.; **Phosphorylation of the PKR activator, RAX, at serine 18 is required for PKR activation and subsequent protein synthesis inhibition following withdrawal of IL-3 from hematopoietic cells**, Joint Cancer Conference of Florida Universities, Amgen young investigators forum, 2004
40. Cao, X., **Bennett, R. L.**, Blalock, W. L., and May, W.S.; **Caspase-2 is involved in proteolytic processing of p21 Bax to p18 Bax which accelerates stress-induced apoptosis**, American Association for Cancer Research annual meeting, Washington D.C., 2003
41. Onel, K., **Bennett, R.L.** and Holloman, W.K.; **The REC1 gene product of *Ustilago maydis*: a putative proofreading exonuclease which functions in cell cycle checkpoint control**. American Academy for Cancer Research Symposium: Cancer and the Cell Cycle, Banff, ALTA, Canada, 1994.

Research Support

Active:

NATL INST OF HEALTH NCI 10/1/15-4/30/2021
Spatio-Temporal Organization of Chromatin and Information Transfer in Cancer
Role: Senior Personnel

NATL INST OF HEALTH NCI 8/11/2016-7/31/2021
The Role of MMSET in the Pathogenesis and Progression of Lymphoid Malignancy
Role: Senior Personnel

FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE 4/2/2018-5/31/2021
Defining and therapeutically targeting HDAC8-driven reprogramming in melanoma brain metastasis development
Role: Senior Personnel

Completed:

Bridge Grant (PI: May, W.S.) 6/1/15 – 5/31/16
UF Health Cancer Center
“Activation of PKR links inflammation to genomic instability”
The major goals of this project are: 1) Elucidate the mechanism(s) by which nuclear PKR activity inhibits DDR signaling 2) Test whether pharmacological inhibition of PKR in mouse models and patient derived xenografts can rescue the MDS phenotype and inhibit MDS evolution to frank acute leukemia 3) Determine whether changes in circulating inflammatory cytokines with age may account for increased PKR expression in NHD13 mice that develop acute leukemia.
Role: Co-Investigator

Bridge Grant Program (PI: May, W.S.) 1/01/15 – 9/30/15
American Society of Hematology (ASH)
“RNA-dependent protein kinase PKR in myelodysplastic syndrome”
The major goals of this project are: 1) Determine the role of PKR in hematopoietic stem/progenitor cell self-renewal and differentiation during normal homeostasis and in response to stress; 2) Determine the role of PKR in development of MDS and hematologic malignancy
Role: Co-Investigator

Richard L. Bennett - CV

TEAM Science Award (PI: May, W.S.)

7/1/13 – 6/30/14

University of Florida Health Cancer Center

Project 2: Determine How PKR may regulate the DNA damage response and MDS evolution to AML

Role: Co- Principle Investigator

2 R01 HL054083 (PI: May, W.S.)

3/09 – 4/13

NIH/NHLBI

The Role of PKR in a Novel IL-3 Signal Transduction Pathway

The specific aims of this project are: 1) Determine the mechanism(s) by which RAX-PKR signal transduction regulates the cell cycle and initiates apoptosis following cellular stress in hematopoietic cells and 2) Determine the significance of PKR in MDS progression to acute leukemia.

Role: Co-Investigator

09BW-06

1/10 – 12/12

Bankhead-Coley Research Program, Florida Dept. of Health

The Role of PKR in Chronic Inflammation and Leukemogenesis

The specific aims of this project are: 1) to determine the role of PKR in chronic inflammation by creating and characterizing transgenic mice expressing either PKR or a dominant negative PKR mutant specifically in hematopoietic cells and 2) to determine how PKR expression and activity link chronic inflammation to leukemogenesis.

Role: Co-Principle Investigator

R01 CA44649 (PI: May, W.S.)

9/30/06 – 7/31/11

NIH/NCI

“IL-3 Growth Factor Signaling

The major goals of this project are: 1) Determine the mechanism by which Bcl2 and p53 binding is regulated by phosphorylation; 2) Determine the mechanism by which p53 binding inhibits Bcl2's survival function; 3) Determine the mechanism by which PP2A regulates Bcl2 function and p53 binding.

Role: Co-Investigator

6BB-14 (PI: May, W. S.)

1/01/07 – 12/31/07

Bankhead-Coley Research Program Bridge Grant, State of Florida

The Role of PKR in a Novel IL-3 Signal Transduction Pathway

The specific aims of this project are: 1) to determine the mechanism by which RAX can regulate PKR signaling protein synthesis and apoptosis and 2) to determine the physiological relevance of RAX on protein synthesis and development of hematopoietic tissue in vivo by employing a knock-out mouse model.

Role: Co-Principle investigator

T32 CA09126 Richard L. Bennett

7/01/01 – 6/30/04

NIH/NCI

Training Grant in Cancer Biology:

The major goals of this project were: 1) Determine the mechanism for RAX-dependent PKR activation. 2) Investigate interesting properties of RAX-PKR signal transduction during stresses such as withdrawal of hematopoietic growth factor IL-3 from dependent cells. 3) To be trained for a career in the field of cancer biology.

Role: Post-doctoral trainee

References

Jonathan D. Licht, M.D.
Director, The University of Florida Health Cancer Center
jdlicht@ufl.edu
352-273-8143

W. Stratford May, M.D., Ph.D.
Professor, Department of Medicine
University of Florida
smay@ufl.edu
352-273-7760

Olga Guryanova, Ph.D.
Assistant Professor, Department of Pharmacology and Therapeutics
University of Florida
oguryanova@ufl.edu
352-294-8590

Kenan Onel, M.D., Ph.D.
Associate Director of Clinical Cancer Genetics and Precision Oncology
Mount Sinai Cancer Center
kenan.onel@mssm.edu
773-633-6477

Additional references available upon request